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Abstract
Objective Seasonal influenza occurs in annual epidemics.
The virus can cause severe illness and concomitant dis-
eases with the highest risk for children, the elderly, and
individuals with disease dispositions. The study objective
is to assess the influenza burden in Germany.
Methods This retrospective claims data analysis used the
HealthRisk Institute research database containing anonymized
data of 4 million individuals. The study period comprised the
influenza season2012/2013 inwhichpatientswith documented
influenza were identified. Disease frequency rates were cal-
culated for a population with disease dispositions and a popu-
lation not at high risk. Disease burden was assessed based on
health-services utilization during the influenza season.Vaccine
rates were calculated by identifying vaccinations.
Results We observed 65,826 patients with influenza,
resulting in 1,160,646 documented influenza cases after
extrapolation. Overall, otitis media and pneumonia was
higher in the influenza-infected population compared to the
non-influenza-infected population and especially high in
children. Hospitalization cost amounted to €87,202,485 with
a mean stay of 7 days, and total outpatient costs were
€14,947,976. Vaccination rates were\4 % for children and
37 % for patients aged[60.
Conclusions Seasonal influenza can cause severe out-
comes with hospitalizations and excess costs. Especially
influenza-infected children are affected by concomitant
diseases with higher disease burden. Furthermore, docu-
mented vaccination rates are quite low.
Keywords Influenza  Claims data  Germany  Burden of
disease
JEL Classification I10  I13
Introduction
Seasonal influenza, an acute viral infection, usually occurs in
thewintermonths and can easily be spread from individual to
individual. In recent years, the seasonal epidemics have
affected approximately 10–20 % of the world’s population
[1]. According to the World Health Organization (WHO),
yearly influenza epidemics lead to serious disease and death
in high-risk populations [2]. In principle, influenza epi-
demics can affect every age group and cause mild-to-severe
illness, whereas the highest risk of a severe course and
concomitant diseases is associated with children, the elderly,
and individuals with a disease disposition [3]. A 30–40 %
rate of all influenza cases during an epidemic have been
reported to be accounted for in children. Moreover, otitis
media and pneumonia are the most frequent concomitant
diseases in children [3–5]. Given the high annual morbidity,
a substantial economic burden arises due to direct medical
cost in the outpatient and inpatient sector. In addition, indi-
rect cost caused by productivity losses due to incapacity to
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Vaccinations can provide an effective tool for the con-
tainment of disease spread [7]. Currently, also against the
background of an increased risk of infection for individuals
with a disease disposition [4], the German Standing
Committee on Vaccination (STIKO) recommends a yearly
influenza vaccination for individuals aged 60 years or older
and a vaccination for certain individuals with an underlying
disease [8]. To date, there is no readily available data for
influenza vaccination rates in Germany for the season
2012/13. Vaccination coverage for 2010/11 was estimated
at 28.3 % in Germany [9].
The number of patients affected by an influenza infec-
tion and seeking health care may serve as an indicator for
the impact of the seasonal burden. Due to the variety of
individuals affected by an influenza epidemic, the severity
of influenza and the vaccination frequency are important
parameters [10]. In addition, the costs and productivity
losses might be substantial [6].
To assess the impact of influenza on the health care system
and estimate the burden of disease caused by influenza in
Germany, a retrospective claims database analysis was per-
formed. For this purpose, individuals with a documented
influenza diagnosis were identified during the influenza sea-
son 2012/13. In terms of higher disease susceptibility, disease
frequency rates were calculated for an at-risk population
and individuals without specific risk profiles. Aside from the
epidemiological analysis, health care resource use and cost
were determined for pharmaceuticals, outpatient care, inca-
pacity to work, and inpatient care. Furthermore, vaccination
rates were approximated for the influenza season 2012/13.
Methods
The study sample consisted of claims data from the Health
Risk Institute (HRI), which includes claims of about 80
different health insurances (out of approximately 130 in
Germany) and comprises the utilization of services on an
anonymous patient by patient individual level. This
research database comprises more than 4 million covered
lives. The sample is representative for the German popu-
lation in terms of age and gender.
According to the Robert Koch Institute (RKI), the
influenza season 2012/13 covers the period of the 40th
calendar week in 2012 until the 20th calendar week 2013
[11]. To identify all patients with a documented influenza
during the influenza season 2012/13, the study period was
from 01 October 2012 to 30 June 2013. This expanded time
frame was chosen due to the practice of quarterly docu-
mentation of diagnosis in the outpatient setting. Patients
were identified by the International Statistical Classification
of Diseases, German Modification (ICD-10-GM) codes for
influenza (J09, J10, J11). Patients were defined as influenza
patients if they had an outpatient or inpatient diagnosis with
at least one of the three influenza codes during the study
period. In addition, the following quarter after the index
quarter, defined as the quarter with the first documented
ICD-10-GM code for influenza, was assessed for each
patient individually. Except for patients diagnosed with
influenza in the 2nd quarter of 2013 (01 April until 30 June)
as per definition the influenza season 2012/2013 ended on
19 May 2013 and all patients had at least 6 weeks to
recover from their influenza infection in the 2nd quarter of
2013. The identified patients were stratified by age groups.
To compare the frequency of influenza within an at-risk
population and individuals without specific risk profiles the
complete HRI research database was divided into two
groups; an at-risk and a not-high-risk population. To assess
the risk disposition, a 1-year pre-observation period before
the beginning of the influenza season 2012/2013 was cho-
sen. The pre-observation period included the 4th quarter
2011 until the 3rd quarter of 2012. Patients were defined as
at-risk if they had at least one diagnosis of diseases of the
respiratory system, the circulatory system, the genitourinary
system, the nervous system (multiple sclerosis), or certain
disorders involving the immune mechanism (including
HIV). These diseases were derived from the recommenda-
tions of the German Standing Committee on Vaccination
[12]. Furthermore, individuals were either required to be
continuously insured for the pre-observation period and
until the end of the influenza season or have been deceased
during the influenza season. In addition, the identified
patients were stratified by age groups.
The relative frequency of the most common concomitant
diseases, otitis media and pneumonia, was evaluated and
compared to individuals not infected with influenza. To
calculate the relative frequency of otitis media, the ICD-10-
GM codes acute otitis media were applied. The timeframe
for the assessment of relative frequency was the influenza
season including the 4th quarter of 2012 until the 2nd quarter
of 2013. Otitis media was assessed in the group of individ-
uals infected by influenza and also in individuals without an
influenza infection in the season 2012/2013. Individuals
assigned to the otitis media group without an influenza
infection were not part of the influenza population.
Similar to the assessment of otitis media frequency, the
relative frequency of pneumonia was evaluated by identi-
fying individuals with an ICD-10-GM code for ‘‘bacterial
pneumonia, not elsewhere classified’’ J15.* in the outpa-
tient or inpatient sector during the 4th quarter of 2012 and
2nd quarter of 2013. Individuals were required to have at
least one coding for bacterial pneumonia during this period
and either be part of the influenza group or have no
influenza infection during the influenza season 2012/2013.
In accordance with the otitis media group, individuals
assigned to the pneumonia group without an influenza
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infection were not part of the influenza population. Fur-
thermore, the relative risk was calculated for both the otitis
media and pneumonia group [13].
Healthcare resource utilization and costs were calculated
from the perspective of the statutory health insurance for
the influenza season 2012/2013. No co-payments or out-of-
pocket payments were taken into account [14]. For each
patient individually, the index and subsequent quarter of
the influenza infection were assessed for resource use and
cost. Direct costs were calculated separately for each
domain—prescriptions, outpatient care, and inpatient
care—based on the influenza-specific resource utilization.
The medicinal treatment was identified by assessing the
prescriptions based on ATC codes for analgesics (N02),
antibiotics (J01), antitussives (R05D), M2-Membranpro-
tein inhibitor (N04BB01), Neuraminidase inhibitor
(J05AH02, J05AH01) and nose spray (R01A, R01B) [15].
Outpatient resource use included number of outpatient
visits based on the documented uniform assessment stan-
dard (EBM) points during the observation period. Outpa-
tient data is only available on a quarterly basis and each
visit cannot be linked to a specific ICD-10-GM code. As a
result, EBM codes were used to identify number of out-
patient visits and costs during the observation period.
Furthermore, the number of incapacity to work days due to
influenza was assessed during the influenza season. The
inpatient scope included the number of hospitalizations
with an influenza coding as the principal or secondary
diagnosis and the corresponding days. The amount of main
and secondary influenza inpatient codes were all stratified
by age groups. Total inpatient cost was extracted directly
from the database and extrapolated. The incapacity to work
days for influenza were assessed and an exemplary calcu-
lation of the productivity loss was performed; assuming an
average cost per incapacity to work day of €176 based on
the lost gross value [16].
To identify influenza vaccinations relevant for the sea-
son of interest, an observational period before and partly
during the influenza season 2012/2013 was chosen, as most
vaccinations for influenza take place during the winter
months beginning in September [8]. The observation per-
iod comprised 01 July to 31 December 2012 and included
all patients with at least one vaccination identified by codes
for vaccination 89111 Influenza (standard vaccination) and
89112 Influenza (other indications).
The results were extrapolated to the German statutory
health insurance (SHI) population. On 31, December 2012
the total German population comprised about 80,523,700
individuals according to the Federal Statistical Office [17].
The underlying claims data sample from the HRI research
database is already adjusted for the age and gender distri-
bution in the German population. Therefore, the extrapo-
lation was calculated by multiplying the results with an
extrapolation factor. This factor is determined through
dividing the German population by the specific study
sample given on 31, December 2012.
Confidence intervals with 95 % confidence level were
calculated by applying the Clopper–Pearson interval. Fur-
thermore, the results were adjusted for the German SHI
population by calculating an adjustment factor of 0.8656
based on the ratio of SHI population 69,704,000 [18] to
German population of 80,523,700.
Results
Influenza cases and rate calculations
Table 1 shows the rate of patients identified in the age
groups ranging from 0 to 1 to above the age of 60. Rate in
percent was calculated based on the underlying German
SHI population. The highest rates of documented influenza
are present in the age group of 2–6 years (3.2 %). Overall,
1.7 % of the SHI population had a documented influenza
infection during the influenza season 2012/2013.
In total, 65,826 documented influenza cases were observed
in the HRI database and extrapolated to the SHI population.
The extrapolation resulted in 1160,646 (95 % CI 1,330,667;
1,351,001) influenza patients during the 4th quarter 2012 until
the 2nd quarter of 2013, adjusted for the SHI population.
Analyses showed a similar rate of documented influenza in
male and female patients for all age groups. Therefore, no
further subgroups for gender are described. The following
Fig. 1 comprises the distribution of influenza cases per age
group based on the observed patient counts.
At-risk population
As described in the Methods section, the risk disposition
was assessed during the 1-year pre-observation period
Table 1 Rate of patients with a documented influenza diagnosis and
total patient counts stratified by age groups
Age groups Rate in % (95 % CI) Totala
0–1 2.47 (2.31; 2.64) 14,952
2–6 3.17 (3.09; 3.26) 91,951
7–12 2.43 (2.36; 2.50) 91,457
13–17 1.93 (1.87; 1.99) 67,778
18–34 1.93 (1.90; 1.96) 271,339
35–59 1.89 (1.87; 1.92) 496,218
C60 0.68 (0.66; 0.70) 126,951
Total 1.67 (1.65; 1.68) 1,160,646
a The extrapolation is based on the sample size of 3,953,260 and an
extrapolation factor of 17.63, adjusted to the SHI population with
86.56 %
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before the beginning of the influenza season 2012/2013. In
total, 3,633,679 individuals were available and continu-
ously enrolled from the beginning of the pre-observation
period until the end or deceased during the influenza sea-
son. The assessment according to ICD-10-GM coding
resulted in 63 % at-risk individuals and 37 % not-high-risk
individuals (Fig. 2).
To compare the influenza disease frequency in the at-
risk and not-high-risk groups, the rate was calculated based
on the underlying German SHI population, at-risk and not-
high-risk, respectively. The following Table 2 comprises
the calculated influenza frequency based on the SHI
extrapolation and the corresponding patient counts with an
influenza diagnosis. At-risk patients, especially children
aged between 0 and 12 had a higher influenza disease rate
than healthy children at the same age groups. Individuals
above the age of 60 had the lowest disease rate in both
groups, whereas children between 0 and 1 had the highest
disease frequency with 4.0 and 2.8 % in both groups. Chi-
square test was applied for significance testing—comparing
the influenza disease frequency in the at-risk and the not-
high-risk group—and resulted in significant p values for all
age groups except for the overall influenza rate. Due to the
distribution of individuals in the different age groups, the
higher proportion of individuals in the age groups 35–59
and 60? and the similar influenza rates within those
groups, the overall influenza rate resulted in 1.70 % for the
at-risk individuals with influenza and 1.72 % for the not-
high-risk group, respectively. Therefore, the overall stan-
dardized influenza rate was calculated to adjust for the age
group distribution. The overall age standardized influenza
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Fig. 2 Distribution of at-risk and not-high-risk individuals in the HRI data pool
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compared to the not-high-risk group of individuals with
influenza with 1.41 %, reflecting the higher influenza rates
in all age groups.
Relative frequency of otitis media and pneumonia
As previously described the calculation of relative disease
frequency for otitis media and pneumonia was performed.
This resulted in an increased frequency of otitis media
compared to the non-diseased population, especially for
children aged between 0 and 6. The following graph shows
that individuals with a documented influenza diagnosis had
a higher rate of otitis media disease than individuals
without an influenza diagnosis during the observation
period. Furthermore, a relative risk of 2.04 [95 % CI
1.9809–2.1068; p\ 0.0001] was calculated for the asso-
ciation with influenza (Fig. 3).
Similarly, the assessment of pneumonia frequency
resulted in a higher number of pneumonia cases, defined as
either pneumonia due to influenza or bacterial pneumonia,
during the influenza season. A relative frequency of 2.5 %
for the influenza population and 0.2 % for the population
not affected by influenza was identified. Children between
the age of 0 and 1 had a relative frequency of 4.5 % in the
influenza population and 0.2 % in the non-diseased popu-
lation. The relative frequency was highest for patients
above the age of 60 (5.5 %). Individuals with influenza
were more likely to contract pneumonia than individuals
without an influenza diagnosis during the observation
period. This is also the case when only comparing bacterial
pneumonia occurrence between the two patient groups and
excluding codes for influenza induced pneumonia. Indi-
viduals with an influenza infection had a higher rate of
bacterial pneumonia in all age groups. The highest rates
were observed in children aged 0–1 (0.8 vs. 0.2 %) and
adults above the age of 60 (0.7 vs. 0.4 %) compared to the
non-diseased population. The relative risk of acquiring a
bacterial pneumonia was almost double [1.84 (95 % CI
1.5870–2.1273; p\ 0.0001)] for influenza patients.
Resource use and cost
Inpatient care
Over 65 % of the inpatient visits were caused mainly by
influenza, as influenza was the principal diagnosis. Espe-
cially, for the age groups 2–6, 7–12, and 13–17 the pro-
portion of influenza principal diagnosis codes was over
80 %. The comparison of mean period per hospitalization
with influenza as a principal diagnosis showed that children
aged between 0 and 1 were in hospital for 5.2 days, in
comparison to individuals aged 60 and above with an
average of 10.4 days caused mainly by influenza.
Overall, 14,952 influenza-related hospitalizations were
identified during the influenza season. These hospitaliza-
tions amounted to 150,436 days and total cost of
€87,202,485 for the SHI population leading to cost per day
of €579.66 for an influenza-related hospitalization. The
average cost per inpatient case treated was €5,832.18.
Patients above the age of 60 were in hospital with a
mean of 13.1 days while children aged between 2 and 6
were in hospital for 6.6 days on average. Overall, the mean
duration of stay was 10.1 days for an influenza-related
hospitalization.
At-risk versus not-high-risk group
In context of the previously described risk analysis for
influenza, the rate of inpatient visits was higher in all age
Table 2 Comparison of influenza frequency in the at-risk and not-high-risk group








0–1 4.04 (3.60; 4.5) 5,812 2.83 (2.49; 3.19) 4,949 \0.0001
2–6 3.98 (3.84; 4.13) 53,769 2.73 (2.62; 2.85) 40,034 \0.0001
7–12 3.18 (3.05; 3.31) 42,989 2.17 (2.09; 2.26) 52,331 \0.0001
13–17 2.51 (2.39; 2.64) 30,846 1.72 (1.64; 1.79) 39,305 \0.0001
18–34 2.41 (2.36; 2.47) 134,778 1.76 (1.72; 1.81) 129,503 \0.0001
35–59 2.13 (2.10; 2.16) 353,020 1.68 (1.64; 1.71) 166,276 \0.0001
C60 0.71 (0.69; 0.73) 126,856 0.42 (0.38; 0.46) 8,364 \0.0001
Total 1.70 (1.68; 1.71) 748,070 1.72 (1.70; 1.74) 440,762 0.0673
a The extrapolation is based on a sample size of 3,633,679 and an extrapolation factor of 19.18, adjusted to the SHI population with 86.56 %
* Chi-square test
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groups for the at-risk population compared to the not-high-
risk group. Children below the age of 18 and individuals
above the age of 60 had the highest rate of influenza-related
hospitalizations. For children below the age of 1, the rate of
influenza-related hospitalizations was highest with 4 % for
the at-risk individuals compared to 3.1 % for the not-high-
risk individuals. The biggest difference between the cal-
culated rates was in the group of individuals aged 60 and
above (3.6 vs. 1.8 %).
Outpatient care
Based on the individual observational period, influenza-
related resource use and cost were assessed. In line with the
determined ATC codes for pharmaceutical treatment,
41.92 % of the influenza patients had a prescription for
antibiotics. Costs were highest for antibiotics and anal-
gesics amounting to €10,124,474 and €6,243,561, respec-
tively. In total, the influenza-related pharmaceutical cost
was €19,846,172 for the influenza season 2012/2013 based
on the SHI population in Germany. The following Table 3
comprises the calculated rate of pharmaceutical use based
on the number of identified patients with a prescription. In
addition, the corresponding cost of the influenza-related
prescriptions were extrapolated.
During the influenza season 2012/2013, 7,682,046
(95 % CI 7,660,540; 7,703,592) outpatient visits and total
cost of €259,044,288 [95 % CI €258,926,618;
€259,161,988] for the extrapolated SHI influenza popula-
tion occurred. This amounted to an average cost per out-
patient visit of €224 and 5.7 outpatient visits on average
within the observation period. In addition, the resource use
and cost of influenza antibody tests were assessed and
extrapolated. EBM codes for Influenza tests amounted to
35,581 coded tests and costs of €542,661. Thorax exami-
nation resulted in a cost of €383,342.
The assessment of the resource use and cost resulted in
total cost for the influenza season 2012/13 of €366,092,945
[95 % CI €365,867,736; €366,318,254] based on the SHI
population. The highest cost were calculated for outpatient
care (€259,044,288), followed by inpatient care
(€87,202,485) and pharmaceuticals (€19,846,172).
Exemplary calculation of the cost of productivity
losses
Out of the influenza population with 65,826 individuals,
23,419 had incapacity to work caused by influenza. In total,
after extrapolation, this resulted in 3,886,210 days of sick
leave with a documented influenza diagnosis and a mean
duration of incapacity to work of 8.15 days. The exem-
plarily calculated cost of productivity losses resulted in
€683,972,960 for the influenza season 2012/2013 assuming
cost per incapacity to work day of €176 [16].
Vaccination rates
Based on documented vaccinations during the 3rd and 4th
quarter of 2012, vaccination rates ranged between 1 and
37 % for the different age groups. Children aged 0–1 had
the lowest vaccination rate with 1.3 %. Individuals above
the age of 60, where an influenza vaccination is indicated,
had the highest vaccination rate with 36.8 %. The extrap-
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Fig. 3 Otitis media frequency rate—comparison between influenza population and non-diseased population
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SHI population with an overall vaccination rate of 13.6 %.
The following Table 4 comprises the vaccination rates and
patient counts with an influenza vaccination.
Over 70 % of the vaccinations were placed with indi-
viduals above the age of 60. In total, only 3.4 % of the
vaccinations were administered to children under the age of
18.
Discussion
The use of German claims data from a large research
database covering approximately 4 million lives serves as a
sophisticated approach to assess the burden of disease from
a health economic perspective. To assess the influenza
season 2012/2013, three study populations were identified
covering patients diagnosed with influenza, individuals
with a disease disposition and patients with an influenza
vaccination. Overall, 1,160,646 influenza patients after
extrapolation were identified in the SHI with total cost of
€366,092,845 for this influenza season. When including the
exemplarily calculated cost for productivity losses, the
total cost was €1,050,065,805. In this section these results
were compared and validated with the existing evidence for
the influenza season 2012/2013 in Germany.
Burden of disease
In Germany, direct and indirect medical costs of diseases
caused by influenza viruses have been estimated to be
1–2.5 billion euros [19]. However, to date, no publications
are available assessing the direct and indirect cost of the
influenza season 2012/13.
The most recent data for the influenza season 2012/2013
is based on the epidemiological report from the German
influenza sentinel system (AGI) of the Robert Koch Insti-
tute covering the time period of the 40th calendar week
2012 until the 20th calendar week 2013. The AGI registers
acute respiratory tract infections in the winter seasons. In
this system, the presence of influenza virus is monitored
through syndromic sentinel surveillance by defining acute
respiratory diseases (ARD) as acute pharyngitis, bronchitis
or pneumonia with or without fever. Season 2012/13
included 834 physicians in 652 sentinel practices, which is
1 % of the primary care physicians in Germany. A sub-
group of participating physicians swab patients with acute
Table 3 Resource use and cost
of influenza-related
pharmaceuticals
Substance Rate in % (95 % CI) Total cost in €a (95 % CI)
Analgesics 18.75 (18.42; 19.08) €6,243,561 (€6,223,951; €6,263,212)
Antibiotics 41.92 (41.43; 42.42) €10,124,474 (€10,100,273; €10,148,712)
Antitussives 10.22 (9.97; 10.46) €1,178,363 (€1,169,521; €1,187,254)
M2-Membranprotein inhibitor 0.03 (0.02; 0.05) €10,168 (€9,355; €11,033)
Neuraminidase Inhibitor 3.55 (3.41; 3.70) €1,160,684 (€1,151,907; €1,169,510)
0.05 (0.03; 0.07) €14,766 (€13,783; €15,801)
Others (nose spray) 12.51 (12.24; 12.78) €1,114,015 (€1,105,414; €1,122,665)
0.00 (0.00; 0.01) €142 (€61; €279)
Total €19,846,172 (€19,815,166; €19,877,200)
a The extrapolation is based on a sample size of 3,953,260 and an extrapolation factor of 17.63, adjusted to
the SHI population with 86.56 %
Table 4 Vaccination rates and
patient counts
Age groups Vaccination rates (95 % CI) Extrapolation of individualsa
0–1 1.29 (1.18; 1.42) 7,812
2–6 2.80 (2.72; 2.89) 81,036
7–12 3.66 (3.58; 3.74) 137,354
13–17 2.82 (2.74; 2.89) 98,823
18–34 2.28 (2.24; 2.31) 319,729
35–59 7.51 (7.47; 7.55) 1,963,168
C60 36.76 (36.65; 36.87) 6,892,817
Total 13.63 (13.60; 13.66) 9,500,740
a The extrapolation is based on a sample size of 3,961,887 and an extrapolation factor of 17.59, adjusted to
the SHI population with 86.56 %
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respiratory tract infections and send samples for testing to
the national influenza reference center. Electronic data of
patients was available from 108 sentinel practices. These
tracked the ICD-10-GM codes J00 to J22, J44.0 and B34.9
[8, 11, 20].
Based on the Infection Protection Act (IfSG), a total of
66,000 laboratory-confirmed acute influenza disease cases
and 10,700 laboratory-confirmed inpatient cases were
reported. The sentinel estimations calculated 7.7 million
excess outpatient consultations, 4.3 million excess cases of
incapacity to work/bed rest, and 32,000 excess hospital-
izations [11].
In comparison, we calculated 1,160,646 influenza
patients with 7.7 million influenza-related outpatient visits,
3.9 million days of incapacity to work, and 14,952 hospi-
talizations during the influenza season.
An estimation of the AGI concerning the number of the
overall influenza patients is missing and therefore a com-
parison with our 1,160,646 influenza patients is limited.
Our study design is based on verified diagnosis codes and
not on laboratory-confirmed disease. However, the RKI
states that only a small number of patients with influenza-
similar symptoms are laboratory screened and an under-
estimation based on the IfSG data is to be expected [11].
Yet the number of influenza-related outpatient visits is
comparable between our study results and the estimation of
the AGI. However, the days of incapacity to work are
lower in our study population. This might be due to the fact
that our database does not include sick leave for
schoolchildren or bed rest. Furthermore, the number of
hospitalizations in our study is almost half the amount as
estimated by the AGI. The RKI states that the number of
hospitalizations especially for infants might be overesti-
mated as different co-circulating pathogens could be the
cause of infection and therefore for hospitalization. This
might be partially due to the fact that the AGI estimation is
not based on inpatient claims but on information given by
the physician if the patient was further transferred to hos-
pital [11].
In general, the surveillance system is based on a less
restrictive definition, as it refers to acute respiratory
infection partly based on more ICD-10-GM codes for a
possible influenza infection than our study design [21].
At-risk population
The assessment of an at-risk and not-high-risk population
during the influenza season 2012/13 was performed with a
wide, conservative scope to identify any individual who
might be at risk and profit from an influenza vaccination.
The majority of individuals in the database (63.3 %) was
thereby defined as being at risk. Out of these, 5.8 % were
aged between 0 and 17 years. The lowest rate of being at-
risk was identified for individuals below the age of 1 year,
which could also be due to the shorter pre-observation
period. In contrast, a recently published cohort study from
the German Health Interview and Examination Survey for
Children and Adolescents assessed chronic and vaccine-
preventable diseases from 2009 to 2012. Vaccine-pre-
ventable diseases included chickenpox, pertussis, and
measles. Chronic diseases were defined as migraine, car-
diac disease, diabetes, epilepsy, febrile convulsion, and
other [22]. This resulted in chronic diseases in 16.2 % of
children aged 0–17 years. Children were divided into age
groups from 0 to 2, 3 to 6, 7 to 10, 11 to 13, and 14 to 17.
The highest prevalence rate for chronic diseases was within
the 14–17 age group. The lowest prevalence rates were
found for children aged 0–2 years with 10.1 % for boys
and 7.7 % for girls, respectively [22]. However, this study
is only remotely comparable to our results as the infor-
mation is based on telephone interviews with the parents
and we applied a broader approach to identify an at-risk
population. Furthermore, the assessed age groups differ
from our analysis.
Relative frequency of otitis media and pneumonia
As previously described, the calculation of relative disease
frequency for otitis media and pneumonia resulted in an
increased prevalence for the diseased population in com-
parison to the non-diseased population and especially for
children aged between 0 and 6 years. The otitis media
frequency was over 30 % for infants aged 0–1 year. A
relative frequency for pneumonia of 2.5 % for the influenza
population and 0.2 % for the population not affected by
influenza was identified. Children between the age of 0 and
1 had a relative frequency of 4.5 % in the influenza pop-
ulation and 0.2 % in the non-diseased population, sug-
gesting a higher disease burden for children with influenza.
Heikkinen et al. assessed the highest average annual rate
of influenza among children below the age of 3, of these
39.7 % developed acute otitis media as a complication [4].
Peltola et al. calculated prevalence rates of acute otitis
media and pneumonia in Finland, showing that 24 % of the
children developed acute otitis media, whereas 9 % of the
individuals aged \17 developed pneumonia [23]. Simi-
larly, Neuzil et al. identified the highest rates of acute otitis
media and lower respiratory tract disease among children
below the age of 2. In addition, acute otitis media was
found in over 50 % of patients hospitalized with a con-
firmed influenza illness [24].
The comparison of published literature with our relative
frequency rates of otitis media and pneumonia shows our
results are in line with calculated prevalence rates and
influenza can be associated with predisposing acute otitis
media.
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Vaccination rates
In general, the calculation of vaccination coverage has
been performed by using billing data and these results can
be validated against available data from other studies [25].
The vaccination rates calculated in our study were highest
for individuals aged 60 and above and lowest for infants
aged 0–1 years. To date, there is no published literature on
the influenza vaccination rate and cost in Germany for
2012. The cost for vaccination can be estimated by mul-
tiplying the cost per dosage with the number of individuals
vaccinated. According to the prices given in the LAUER
Taxe, individuals aged between 2 and 6 years receive ‘‘live
attenuated influenza vaccine (LAIV)’’ at €23.49 per dosage
and all others receive ‘‘trivalent inactive influenza vaccine
(TIV)’’ at €6.27 per dosage [Lauer Taxe]. In total, esti-
mated cost for influenza vaccination are €60,965,073. The
estimated cost is relatively low in comparison to the cal-
culated direct cost of €366,092,845 for the influenza season
2012/13.
Damm et al. estimated the yearly baseline coverage for
individuals in different age groups, starting with children
below the age of 2 up to adults aged 70 years and over in
Germany. As a result, children below the age of 1 were
assumed to have no baseline vaccination coverage, while
vaccination coverage rates ranged between 11 and 23.6 %
for children aged between 1 and 17 years. Coverage was
estimated to grow with increasing age and was highest for
the elderly population [26].
Contrary to Damm et al. who calculated the yearly
coverage, Bo¨hmer et al. estimated the seasonal influenza
vaccination uptake. Their study based on telephone inter-
views from the German Health Update (GEDA10) with
n = 22,050 and a smaller GEDA10-follow up (n = 2,493)
which were both stated to be representative of the general
population aged C18 years living in Germany. Seasons
2008/09, 2009/10 and 2010/11 were assessed. The seasonal
influenza vaccine uptake varied between 26.6 % in
2009/10 (n = 13,040) and 29.8 % in 2008/09. Individuals
not assigned to the health care worker group and/or
chronically ill group, had a vaccination rate of 14.8 % in
season 2010/11 (n = 2,492). Vaccination rates were lowest
for individuals aged 18–29 years both for the target and the
non-target group [9]. Similar vaccination ranges were
observed in several other studies conducting telephone
interviews [27–29].
The only two studies using billing data in this field of
research were conducted by Reuss et al. and Schro¨der-
Bernhardi et al., the latter was based on the IMS Vaccine
Analyzer covering 37 pediatric practitioners and 145 gen-
eral practitioners for the vaccination season July to March
2011/2012 and the following vaccination seasons
2012/2013 and 2013/2014. The analysis was performed for
children and adolescents aged 0–18. The results were
extrapolated to the German population and resulted in
vaccination rates of 4.3 % in 2011/2012, 3.8 % in
2012/2013, and 4.2 % 2013/2014 [30].
Reuss et al. determined influenza vaccination coverage
in the 2004/05, 2005/06, and 2006/07 seasons based on
billing data of the German associations of statutory health
insurance physicians. Vaccinations were identified by
codes for vaccination. Vaccinations were usually admin-
istered from September to December. The vaccination rate
was 49 % for individuals above the age of 60. In all three
assessed seasons, vaccination rates in the population aged
above 60 were increased in relation to the individuals’ age.
In the group of 60- to 64-year-olds, the average rate was
38 %; for the 65- to 69-year-olds, 46 % were stated; for
the70- to 74-year-olds, the rate was 51 %; and for those
older than 75, a vaccination rate of 54 % was reported [31].
The additional literature search revealed that there are
no readily available vaccination coverage rates obtainable
for the season 2012/13 in Germany using a data source
comparable to our study design. The most recent data
comprises results based on the IMS Vaccine Analyzer
referring to a different time frame (July to March
2012/2013) and might be biased due to selection of pedi-
atricians and general practitioners taking part in an ana-
lyzer program not representable for the German population
[30]. However, our calculated vaccination rates for chil-
dren and adolescents aged 0–17 with 3.4 % are comparable
to those published (3.8 % for 0–18 years old). In general
consistent with our vaccination rates, the trend of higher
vaccination coverage accompanied by higher age can also
be observed in the literature. The previous passages clearly
indicate that the comparability is limited due to the dif-
ferent influenza seasons, target populations and reported
age groups [25, 29, 31, 32].
Limitations
This study is limited by the nature of the data source. Claims
data are recorded for accounting purposes and not for clin-
ical research. As a result, it is not possible to characterize
patients by clinical parameters such as disease severity or to
see the physician’s intention for each intervention. Data on
the incidence of influenza are limited by the difficulties
inherent in distinguishing influenza from other influenza-
like illnesses [33]. Furthermore, copayments and out-of-
pocket payments are not included in the analyses which
might underestimate the overall burden of disease.
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Conclusions
The results of our retrospective analysis suggest an
increased disease burden of influenza for children aged
between 0 and 17 years. In total, 22.9 % of the influenza
infections were documented for individuals below the age
of 18. In addition, the relative frequency of otitis media and
pneumonia was highest for children aged 0–6 years. The
relative risk of acquiring an otitis media infection with
influenza was twice as high as for individuals without
influenza. In comparison, the calculated vaccination rates
were relatively low for all age groups and especially for
children and adolescents under the age of 18 with 3.4 %.
Moreover, the conservative approach of identifying at-risk
individuals showed that these individuals had a higher
influenza frequency than individuals without a disease
disposition.
These results suggest that given the calculated low cost
of influenza vaccination, a higher vaccination rate might
lower the disease burden for children and individuals with
a disease disposition and decrease the seasonal cost of
influenza from a health insurance perspective.
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